EcoDrugPlus

Tubulin Beta-2a Chain-Like

Ensembl ID : ENSHCOG00000020921
Gene Symbol: LOC109521377
3 Cross references
183 Possible Orthologues:

Tubulin Beta-4b Chain-Like

Ensembl ID : ENSHCOG00000015751
Gene Symbol: LOC109521438
2 Cross references
137 Possible Orthologues:

Tumor Protein P53

Ensembl ID : ENSHCOG00000011113
Gene Symbol: TP53
3 Cross references
232 Possible Orthologues:

Type-2 Angiotensin Ii Receptor-Like

Ensembl ID : ENSHCOG00000003490
Gene Symbol: LOC109524378
3 Cross references
185 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSHCOG00000014801
Gene Symbol: TYR
3 Cross references
202 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSHCOG00000006539
Gene Symbol: TYR
4 Cross references
198 Possible Orthologues:

Tyrosine 3-Monooxygenase/tryptophan 5-Monooxygenase Activation Protein Theta

Ensembl ID : ENSHCOG00000015914
Gene Symbol: ADAM17
3 Cross references
208 Possible Orthologues:

Tyrosine Hydroxylase

Ensembl ID : ENSHCOG00000009036
Gene Symbol: TH
3 Cross references
187 Possible Orthologues:

Tyrosine Kinase 2

Ensembl ID : ENSHCOG00000016457
Gene Symbol: TYK2
3 Cross references
195 Possible Orthologues:

Tyrosine Kinase With Immunoglobulin Like And Egf Like Domains 1

Ensembl ID : ENSHCOG00000005202
Gene Symbol: TIE1
3 Cross references
205 Possible Orthologues:

Tyrosine-Protein Kinase Fyn

Ensembl ID : ENSHCOG00000006889
Gene Symbol: LOC109524890
4 Cross references
196 Possible Orthologues:

Tyrosine-Protein Kinase Itk/tsk-Like

Ensembl ID : ENSHCOG00000002937
Gene Symbol: LOC109524354
3 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).